Maternal serum ischemia modified albumin as a marker for hypertensive disorders of pregnancy: a pilot study

Sapna Vyakaranam1*, Aparna Varma Bhongir1, Dakshayani Patlolla1, Rekha Chintapally2

INTRODUCTION

Hypertensive disorders complicating pregnancy are common cause of the maternal morbidity and mortality. The spectrum includes pregnancy induced hypertension, preeclampsia, eclampsia.1 Though various studies have mentioned the etiopathogenesis of preeclampsia, even then it is regarded as "disease of theories".2

The normal placental development in early pregnancy involves the plugging of spiral arteries with endovascular trophoblast. Defective endovascular trophoblastic invasion and inadequate remodeling of uterine spiral arteries cause vasoconstriction and vasoreactivity in placenta.3 This causes hypoxic environment and generation of reactive oxygen species (ROS), leads to oxidative stress which is considered in the pathogenesis of preeclampsia.4,5

Serum Ischemia Modified Albumin (IMA) is recently been used as a serum biomarker for cardiac ischemia in acute coronary syndrome.6 The N-terminus of albumin is altered in response to hypoxic environment and forms IMA. As hypoxia and oxidative stress are considered in
etiology and pathogenesis of preeclampsia, serum IMA levels are also elevated in preeclampsia. 7,8

Previous studies have mentioned elevated levels of serum IMA in preeclampsia when compared with normal pregnancy. 9,10 Very few studies have demonstrated the correlation of serum IMA with severity of preeclampsia. 11,12 Contradiction to these studies also exists. 13 All these studies were done in preeclampsia.

Hence the aim of our study is to determine maternal serum IMA and see if this marker can discriminate hypertensive disorders of pregnancy (Pregnancy induced hypertension, preeclampsia) from normal pregnancy.

METHODS

The present study included pregnant women aged 18-30 years and ≥32 weeks of gestation attending the antenatal clinic in Obstetrics department. Institutional ethics committee clearance and written informed consent from participants were obtained.

Study population was divided into 3 groups. Eighteen women with Pregnancy Induced Hypertension (PIH) & 19 women with preeclampsia (PE) were considered as cases. Control group included 19 normotensive women (NP).

PIH group included pregnant women with BP ≥140/90 mm of Hg and without proteinuria.

PE group included pregnant women with BP ≥140/90 mm of Hg and with proteinuria given as 1+ in dipstick or Pr/Cr ratio as ≥0.3 mg/gm. 14

Cases and control groups were matched with age and gestational age. Pregnant women with bad obstetric history, twin pregnancy, previous pregnancy with hypertensive disorders, previous medical diseases like diabetes mellitus, essential hypertension, ischemic heart disease, peripheral vascular diseases were excluded from the study.

Blood pressure was measured with oscillometric digital sphygmomanometer (Omron HEM-780N3) on 2 separate occasions 4 hours apart and average was taken. Under strict aseptic conditions 5 ml of blood sample was collected by venous puncture, into properly labeled plain polystyrene tubes. The samples were collected, handled and transported to the lab according to the guide lines given by clinical and laboratory standards institute/NCCLS (National Clinical Chemistry Laboratory Standards). 15,16 Blood samples were centrifuged at 10000 rpm for 10 min and the serum was collected in vials and stored at -80°C till the analysis. Frozen samples were thawed to room temperature before analysis.

Serial IMA was estimated by human ischemia modified albumin, IMA ELISA Kit provided by WUHAN EIAAB science co. Ltd USCN LIFE on Dade Behring BEP 2000 version. Samples were added to Purified Human IMA coated antibody microtiter wells with biotin conjugated antibody preparation specific for IMA and avidin conjugated to Horse Radish Peroxidase (HRP) was added to microtiter plates and incubated. The TMB substrate was added to each well. Only those wells that contain IMA, biotin conjugated antibody and enzyme conjugated Avidin exhibited a color change. The enzyme substrate reaction was terminated by addition of sulphuric acid and color change was read at 450 ± 2 nm spectrophotometrically with in 15 min.

Standardization of serum IMA estimation

The working standard of IMA was reconstituted and diluted from aqueous stock solution of 500 ng/ml concentration. The stock standard was diluted to 7 different concentrations as, 500 ng/ml, 250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.2 ng/ml, 15.6 ng/ml, 7.8 ng/ml and the last tube with standard diluent was blank as 0 ng/ml. A standard curve was created by generating a four parameter logistic curve fit (4-PL). The concentration of IMA in the samples was determined by comparing the O.D. of the samples to the standard curve.

The standard curve is represented in Figure 1.

Random midstream urine was collected for protein estimation. The samples were collected and transported according to the standard guidelines. 17 Semi quantitative dip stick method was used to estimate the proteins. Two readings of 1+ for samples at two different occasions were considered as diagnostic of preeclampsia. The
pregnant women were followed till delivery for maternal outcome. Fetal birth weight was obtained on digital weigh scale (SECA 354/364).

**Statistical analysis**

The data was processed on MS excel work sheet. The results were analyzed by student’\( t\) test and Chi square test. A 2-tailed probability value of 0.05 was considered as statistically significant. The critical values of IMA were obtained by Receiver Operation Characteristics (ROC) curves. All the statistical analysis were carried out using MedCalc Statistical Software version 12.7.8 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2014.)

**RESULTS**

The study population included 19 Normotensive Pregnant women (NP), 18 women with Pregnancy Induced Hypertension (PIH), 19 women with preeclampsia (PE).

Demographic, clinical and biochemical characteristics in study population are represented in Table 1.

**Table 1: Demographic, clinical and biochemical characteristics in study population.**

<table>
<thead>
<tr>
<th></th>
<th>NP (19)</th>
<th>PIH (18)</th>
<th>PE (19)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>22.68 ± 2.45</td>
<td>21.67 ± 2.09</td>
<td>22.95 ± 2.93</td>
<td>0.27</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>36.26 ± 4.34</td>
<td>38.33 ± 2.38</td>
<td>36.21 ± 2.59</td>
<td>0.08</td>
</tr>
<tr>
<td>SBP (mm of Hg)</td>
<td>112.63 ± 7.33</td>
<td>139.44 ± 2.36</td>
<td>147.89 ± 9.76</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>DBP (mm of Hg)</td>
<td>73.16 ± 7.49</td>
<td>95 ± 7.07</td>
<td>101.58 ± 11.67</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Urine proteins</td>
<td>Nil</td>
<td>19</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Trace</td>
<td>Nil</td>
<td>5</td>
<td>1</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>+/- 2+/3+</td>
<td>Nil</td>
<td>Nil</td>
<td>5/8/5</td>
<td></td>
</tr>
<tr>
<td>Serum IMA (ng/ml)</td>
<td>35.47 ± 11.58</td>
<td>36.24 ± 14.51</td>
<td>56.84 ± 21.57</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

NP: Normotensive pregnancy; PIH: Pregnancy induced hypertension; PE: Preeclampsia *Significant P <0.05

The mean age and gestational age were not statistically significant. There was a significant difference in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and urinary proteins among the groups.

The mean serum IMA levels in PE (56.84 ± 21.57 ng/ml) were significantly elevated when compared with PIH (36.24 ± 14.51 ng/ml) and normotensive pregnancy (35.47 ± 11.58 ng/ml) with P value <0.001.

**Table 2: Maternal and fetal outcomes in the study population.**

<table>
<thead>
<tr>
<th></th>
<th>NP (19)</th>
<th>PIH (18)</th>
<th>PE (19)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VD</td>
<td>14</td>
<td>8</td>
<td>3</td>
<td>0.01*</td>
</tr>
<tr>
<td>LSCS</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>IUD</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
<td>1</td>
</tr>
<tr>
<td>Fetal outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Term</td>
<td>19</td>
<td>16</td>
<td>15</td>
<td>0.03*</td>
</tr>
<tr>
<td>Preterm</td>
<td>Nil</td>
<td>2</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Birth weight (Kg)</td>
<td>2.82±0.03</td>
<td>2.88±0.38</td>
<td>2.47±0.51</td>
<td>0.006*</td>
</tr>
</tbody>
</table>

NP: Normotensive pregnancy; PIH: Pregnancy induced hypertension; PE: Preeclampsia; *Significant P <0.05

Maternal and fetal outcomes in the study population are represented in Table 2.

In NP group 74 % of the women had Full Term Normal Vaginal Delivery (FTNVD) where as it was 44 % and 16 % in PIH and PE groups respectively.

In NP group all the new born were full term whereas 2 of 18 in PIH and 4 of 19 in PE were preterm. The fetal birth weight was significantly low in PE group when compared with NP and PIH groups.

ROC analysis of serum IMA in hypertensive disorders of pregnancy are represented in Table 3.

Serum IMA with a cutoff of 38.33ng/ml had greater sensitivity (88.9%) and specificity (73.7%) for preeclampsia than for PIH with a cutoff of 22.9 ng/ml, sensitivity (27.8%) and specificity (89.5%).

Figure 2 and 3 - Represents the interactive dot diagram with cutoff, sensitivity and specificity of normal pregnancy with PIH and PE respectively.

Figure 4 - Represents comparison of ROC curves in PIH and preeclampsia.
Table 3: ROC analysis of serum IMA in hypertensive disorders of pregnancy.

<table>
<thead>
<tr>
<th>Cut-off</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>AUC</th>
<th>P of AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIH</td>
<td>≤22.9</td>
<td>27.8%</td>
<td>89.5%</td>
<td>0.50</td>
</tr>
<tr>
<td>PE</td>
<td>&gt; 38.33</td>
<td>88.9%</td>
<td>73.7%</td>
<td>0.81</td>
</tr>
</tbody>
</table>

PIH: Pregnancy induced Hypertension, PE: Preeclampsia; AUC: Area under curve; *Significant P value <0.05

DISCUSSION

In our study we observed elevated levels of serum Ischemia Modified Albumin (IMA) in preeclampsia when compared with PIH and normotensive pregnancy.

Serum IMA is formed in response to hypoxia or free radical injury to N terminus (asp-ala-his-lys) of albumin.\(^18\) It is been used as a marker of cardiac ischemia. Its levels are also elevated in conditions related to oxidative stress like scleroderma, end stage renal disease, peripheral vascular disorders and any events associated with hypoxia.\(^19-21\)

Preeclampsia is characterized by poor placental perfusion due to vasospasm of uterine spiral arteries, which generate hypoxia and oxidative stress.\(^22-24\) Hence serum IMA a marker of oxidative stress and hypoxia is elevated in preeclampsia. Our study is in accordance with the studies done by Ustan Y et al.,\(^11\) Gafsov et al.,\(^12\) Jyothi et al.\(^10\) and Jyotirmayee et al.\(^9\) who observed elevated levels of serum IMA in preeclampsia in third trimester and Papageoghiour AT et al.\(^3\) who observed changes in first trimester.

Gafsov et al.\(^12\) studied non pregnant, normal pregnant and preeclampsia women at 30 weeks of gestation. A significant increase in serum IMA was observed in both pregnant and preeclamptic women when compared with non-pregnant women. The elevated levels of serum IMA continued till delivery. Jyotirmayee et al.\(^9\) and Jyothi et al.\(^10\) in their studies done on pregnant women at 30 ± 4 weeks and 34 ± 4 weeks of gestation respectively, found an elevated levels of serum IMA in preeclampsia.

Papageoghiour et al.\(^3\) found an early elevation of serum IMA, i.e. at 11-12 weeks of gestation in women who later developed preeclampsia. It was stated that poor placental perfusion causes hypoxia and oxidative stress which leads to preeclampsia. These changes occur during the development of placenta. Hence serum IMA can be an early marker of preeclampsia.

In few studies increased serum IMA was attributed to the overproduction or decreased clearance.\(^25\) Though albuminuria is characteristic of preeclampsia, IMA was not present in the urine indicating an extra renal clearance.\(^26\)

In our study ROC curve analysis the cutoff 38.33 ng/ml resulted sensitivity and specificity of 88.9% and 73.7%.
respectively. Ustan Y et al. in his study observed that with a cutoff 0.31 ABU, serum IMA had 80% sensitivity and 77.8% specificity for preeclampsia.

In these studies serum IMA was estimated by an indirect method of albumin cobalt binding colorimetric assay (ACB) proposed by Bar-O et al. It is based on the principle that IMA loses its ability to bind to heavy metals like Co. In ACB method a known amount of cobalt was added to serum and the unbound cobalt was measured by the intensity of colored complex with dithiothreitol. IMA was expressed as U/ml. One IMA unit was defined as µgm of free Cobalt in the reaction mixture per ml of serum sample. This method would not give the concentration of serum IMA.

In our study we directly and quantitatively measured the serum IMA by ELISA method. The results obtained in our study are in accordance with the previous studies but the values cannot be compared due to the variation in the methodology.

This is the first study in which serum IMA in pregnant women was quantitatively estimated by ELISA method.

In conclusion serum IMA levels are elevated in preeclampsia which can be estimated quantitatively. Further studies focusing on serum IMA as an early marker of preeclampsia should be done to identify woman who may benefit from early intervention. Our study is limited by the sample size.

ACKNOWLEDGEMENTS

Research reported in this publication was conducted by scholars in the Fogarty international center of the national institutes of health training program under award number D43 TW 009078. The content is solely the responsibility of the authors and does not necessarily represent the official views of the national institutes of health.

We would like to thank Dr. P. S. Reddy, Chairman, Share India for constant support and providing the funds. Dr. Clareann H. Bunker, Associate professor, Graduate school of Pittsburg for editing the paper. We would like to thank Dr. P. Satyanarayana, HOD department of Lab Medicine, nursing staff of department of obstetrics and lab technicians for their support in collection and storage of samples.

Funding: The study was funded by SHARE INDIA, Mediciti Institute of Medical sciences

Conflict of interest: None declared

Ethical approval: The study was approved by the institutional ethics committee

REFERENCES


